Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 8/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 8/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL19548432 | 1.00 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL28757866 | 0.86 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| Valine SCHEMBL11294936 | 0.85 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL28133160 | 0.84 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| Valine SCHEMBL28133161 | 0.84 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| Alanine SCHEMBL11041073 | 0.84 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL7597181 | 0.82 | SLC7A5 (0.71) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| Valine SCHEMBL5697736 | 0.82 | SLC7A5 (0.71) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL2875734 | 0.81 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL10725920 | 0.81 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872261-B2 | Lipoprotein targeting protease inhibitors and uses | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230201298-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220168379-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-06-02 | — | — | US | disclosed |
| US-20200078434-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2020-03-12 | — | — | US | disclosed |
| US-20170319643-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-11-09 | — | — | US | disclosed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872261-B2 | Lipoprotein targeting protease inhibitors and uses | SERPINB1, APOB, APOL1 | SLC7A5 557/4885SLC1A3 2752/4885SLC1A2 3510/4885 |
| US-20200078434-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | SLC7A5 557/4885SLC1A3 2752/4885SLC1A2 3510/4885 |
| US-20170319643-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | SLC7A5 557/4885SLC1A3 2752/4885SLC1A2 3510/4885 |
| US-20230201298-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | HPN, SERPINB1, PEPD | SLC7A5 430/4885SLC1A3 2868/4885SLC1A2 3583/4885 |
| US-20220168379-A1 | LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES | SERPINB1, APOB, APOL1 | SLC7A5 557/4885SLC1A3 2752/4885SLC1A2 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.